Skip to main content
OpenTrials
Completed

NCT Number: NCT04280315

Investigation of the Skin Barrier in Patients With Type 1 Diabetes

This study is a case-control study comparing the skin barrier between 50 T1D patients with healthy controls in 3 age-strata including both pediatric and adult patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Steno Diabetes Center Copenhagen, Gentofte Municipality, Capital Region, Denmark

Loading trial locations.

About this study

The skin is a crucial barrier against external allergens and irritants. Therefore the function of the skin barrier is central regarding evolvement of eczema. In patients with type 1 diabetes (T1D) using insulin pumps and/or glucose sensor, eczema is unfortunately a frequent reaction. The skin consists of three layers: epidermis, dermis and subcutaneous fat, whereas epidermis is most determining regarding skin barrier. Epidermis can further be subdivided, where stratum corneum (SC) is the outer part, which means most regarding vulnerability towards external allergens.

The function of the skin barrier can be investigated by non-invasive methods using transepidermal water loss (TEWL), which shows the water vapour flux from the skin. Besides SC can be determined using the tape strip method, where few SC cells are peeled off and thereby can be analyzed with mass-spectrometry. Natural moisturizing factors (NMF) is though one of the very important functionalities of the SC, which are determined by the amount of 2-pyrrolidone-5-carboxylic acid (PCA). Besides, the lipid distribution, presence of antimicrobial peptide and cytokine response give as well important information regarding the skin barrier.

Dermatological manifestations of T1D are quite frequent and have been shown to be related to glycemic control, placing dermatological manifestations as a precursor of other microvascular complications11. There is a lack of studies regarding skin barrier function in patients with T1D, and especially in a pediatric study population. Therefore, this case-control study will be conducted investigating skin barrier function in pediatric patients with T1D compared to healthy controls in order to both meet this lack of knowledge, but as well to improve the prevention of skin problems to devices used in T1D-treatment.

The examination program of just one visit per participant consists of:

  • TEWL-measure at forearm and buttock
  • Buccal swab regarding filaggrin gene status
  • Microbiological swab from the skin at forearm and buttock
  • 2X11 tape strips from the skin at foream and buttock to be analyzed for NMF, Lipid, Cytokines, Antimicrobial peptide and Dermal Topographical Index as well as protein content using SquameScan
  • Measure of skin PH, hydration and sebum content at forearm and buttock
  • Capillary Blood Glucose
  • Survey regarding atopic and dermatological symptoms

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Cases:

Inclusion criteria

  • Diagnosed with type 1 diabetes, more than 6 months ago

Exclusion criteria

  • Skin lesions at both buttocks and forearms so investigation can not be done
  • Known skin diseases with decreased barrier function like atopic dermatitis, psoriasis and allergic contact dermatitis
  • Active infectious disease
  • Use of immunosuppressive medication e.g. steroids
  • Lack of language competence in Danish

Controls:

Inclusion criteria

  • Diagnosed with Tourettes or Headache OR sibling for patients in the 1813-clinic at Pediatric Emergency Toom OR Hospitalized patients at Pediatric department OR Parents to alle these

Exclusion criteria

are equal to exclusion criteria in cases

Treatment and study plan

Primary outcomes

  1. TEWL

    Time frame: Baseline

    Transepidermal Water Loss measured by an Aquaflux AF1000

Secondary outcomes

  1. Skin barrier properties described with Tape Strips

    Time frame: Baseline

    Tape strips will be analyzed according to Natural Moisturizing Factors

  2. Filaggrin mutation Status

    Time frame: Baseline

    Filaggrin DNA status regarding common SNPs in DNA

  3. Skin pH

    Time frame: Baseline

    Measured with DermaUnit SSC3 Skin pH-Meter

  4. Skin hydration

    Time frame: Baseline

    Measured with DermaUnit SSC3 Corneometer

  5. Sebum content in skin

    Time frame: Baseline

    Measured with DermaUnit SSC3 Sebumeter

Sponsors and collaborators

Lead sponsor

Jannet Svensson

Other

Registry information

Official study title

Investigation of the Skin Barrier in Patients With Type 1 Diabetes - a Case-control Study

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Feb 21, 2020
Registry last updated
Feb 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.